Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $38.50.

ALGS has been the topic of several research reports. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Lake Street Capital started coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price objective for the company. Westpark Capital started coverage on shares of Aligos Therapeutics in a research note on Thursday, March 26th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS opened at $5.59 on Friday. The business has a 50-day moving average of $5.68 and a two-hundred day moving average of $7.19. The firm has a market capitalization of $34.60 million, a PE ratio of -0.64 and a beta of 2.26. Aligos Therapeutics has a 12 month low of $4.80 and a 12 month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. As a group, research analysts anticipate that Aligos Therapeutics will post -7.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALGS. Woodline Partners LP acquired a new position in shares of Aligos Therapeutics during the first quarter worth about $2,602,000. Geode Capital Management LLC grew its stake in shares of Aligos Therapeutics by 21.3% in the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after buying an additional 5,978 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Aligos Therapeutics in the second quarter valued at about $100,000. Vanguard Group Inc. raised its holdings in shares of Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after buying an additional 31,913 shares during the period. Finally, Squarepoint Ops LLC lifted its position in Aligos Therapeutics by 64.0% during the 3rd quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock worth $299,000 after acquiring an additional 11,904 shares in the last quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.